Additional limitations include the lack of matched/paired non-cancer tissue and the lack of germ-line testing to identify patients with Lynch syndrome as well as tumor heterogeneity, which can contribute to the variability of HER2 status across tumor types. The gene discussed is ERBB2; the disease is neoplasm.